The 2014-2016 Ebola outbreak in West Africa has triggered accelerated development of several preventive vaccines against Ebola virus. Under the EBOVAC1 consortium, three phase I studies were carried out to assess safety and immunogenicity of a two-dose heterologous vaccination regimen developed by Janssen Vaccines and Prevention in collaboration with Bavarian Nordic. To describe the immune response induced by the two-dose heterologous vaccine regimen, we propose a mechanistic ODE based model, which takes into account the role of immunological memory. We perform identifiability and sensitivity analysis of the proposed model to establish which kind of biological data are ideally needed in order to accurately estimate parameters, and additionally, which of those are non-identifiable based on the available data. Antibody concentrations data from phase I studies have been used to calibrate the model and show its ability in reproducing the observed antibody dynamics. Together with other factors, the establishment of an effective and reactive immunological memory is of pivotal importance for several prophylactic vaccines. We show that introducing a memory compartment in our calibrated model allows to evaluate the magnitude of the immune response induced by a booster dose and its long-term persistence afterwards.

Department of Pathology and Cell Biology Columbia University Medical Center New York New York USA

INRIA SISTM team Talence France

INSERM U1219 Bordeaux Population Health Université de Bordeaux Bordeaux France

Janssen Pharmaceutica N 5 Beerse Belgium

Janssen Vaccines and Prevention B 5 Leiden The Netherlands

Université de Bordeaux CNRS Bordeaux INP IMB UMR 5251 F 33400 Talence France

Vaccine Research Institute Créteil France

Citace poskytuje Crossref.org